Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Acid a-Glucosidase Deficiency (Glycogenosis Type II, Pompe Disease)

Raben, Nina, Plotz, Paul, Byrne, Barry · 2002 · Current Molecular Medicine

Abstract

Glycogenosis type II (GSDII, Pompe disease) is an autosomal recessive lysosomal storage disease caused by a deficiency of acid alpha-glucosidase (acid maltase, GAA). The enzyme degrades alpha -1,4 and alpha -1,6 linkages in glycogen, maltose, and isomaltose. Deficiency of the enzyme results in accumulation of glycogen within lysosomes and in cytoplasm eventually leading to tissue destruction. The discovery of the acid a-glucosidase gene has led to rapid progress in understanding the molecular basis of glycogenosis type II and the biological properties of the GAA protein. The last decade has seen several developments: 1) extensive mutational analysis in patients with different forms of the disease, 2) characterization of the enzyme biosynthesis, processing, and lysosomal targeting, 3) generation of knockout mouse models, 4) development of viral vectors for gene replacement therapy, 5) the production of recombinant human enzyme, and 6) a shift in the enzyme replacement therapy approach from theory to practice. It is anticipated that the enzyme replacement therapy will be widely available for human use in the near future. Several recent reviews (including the most comprehensive one by R. Hirschhorn and A. Reuser [1]), address clinical, biochemical and genetic aspects of the disease, as well as development of new therapies for GSDII [2, 3, 4]. In this article we will review recent findings in the area including rapidly accumulating molecular genetic data (more than 20 mutations need to be added to the list), transcriptional control of gene expression, studies in mouse models, and new approaches to gene therapy. We will also highlight some emerging questions following the introduction of enzyme replacement therapy.

Overview

Integrity signals

Registry

Crossref · 10.2174/1566524024605789

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 243

Metadata

Authors
Raben, N., Plotz, P., & Byrne, B.
Affiliations
National Institutes of Health (US)
Venue
Current Molecular Medicine
Published
2002-03-01
Volume
2
Issue
2
Pages
145-166
ISSN
1566-5240 (ISSN-L)
OpenAlex
W2115510312
Cited by
241
References
0
Citations by year
2026: 8 · 2025: 7 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 13 · 2018: 4 · 2017: 15 · 2016: 9 · 2015: 9 · 2014: 9 · 2013: 14 · 2012: 8
FWCI
7.19
Type
journal article
Language
en
Open access
closed
Locations
  • Current Molecular Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
Pompe disease, acid alpha-glucosidase deficiency, lysosomal storage disease, GAA gene mutations, gene expression regulation, knockout mouse models, gene therapy, viral vectors, recombinant enzyme replacement therapy
MeSH terms
Adult, alpha-Glucosidases, Animals, Child, Preschool, Female, Genotype, Glycogen Storage Disease Type II, Humans, Infant, Male, Models, Genetic, Mutation, Phenotype, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acid a-Glucosidase Deficiency (Glycogenosis Type II, Pompe Disease). https://app.cochat.ai/papers/10.2174/1566524024605789
The paper
Raben, N., Plotz, P., & Byrne, B. (2002). Acid a-Glucosidase Deficiency (Glycogenosis Type II, Pompe Disease). Current Molecular Medicine. https://doi.org/10.2174/1566524024605789

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.